Insider Selling: Moderna, Inc. (NASDAQ:MRNA) Director Sells 15,000 Shares of Stock

Moderna, Inc. (NASDAQ:MRNA) Director Noubar Afeyan sold 15,000 shares of Moderna stock in a transaction on Wednesday, April 10th. The stock was sold at an average price of $107.12, for a total transaction of $1,606,800.00. Following the sale, the director now owns 2,071,931 shares of the company’s stock, valued at $221,945,248.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Noubar Afeyan also recently made the following trade(s):

• On Wednesday, April 3rd, Noubar Afeyan sold 15,000 shares of Moderna stock. The stock was sold at an average price of $101.68, for a total transaction of $1,525,200.00.
• On Wednesday, March 27th, Noubar Afeyan sold 15,000 shares of Moderna stock. The stock was sold at an average price of $109.06, for a total transaction of $1,635,900.00.
• On Wednesday, March 20th, Noubar Afeyan sold 15,000 shares of Moderna stock. The stock was sold at an average price of $102.39, for a total transaction of $1,535,850.00.
• On Wednesday, March 13th, Noubar Afeyan sold 15,000 shares of Moderna stock. The shares were sold at an average price of $108.54, for a total transaction of $1,628,100.00.

Moderna Price Performance

Shares of MRNA stock traded down $1.87 on Friday, reaching $105.14. 2,415,948 shares of the company were exchanged, compared to its average volume of 4,300,259. The company has a market cap of $40.26 billion, a price-to-earnings ratio of -8.47 and a beta of 1.62. The business has a 50-day moving average price of $99.71 and a 200 day moving average price of $93.52. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.36 and a current ratio of 3.42. Moderna, Inc. has a 1 year low of $62.55 and a 1 year high of $163.24.

Moderna (NASDAQ:MRNA) last released its earnings results on Thursday, February 22nd. The company reported $0.55 EPS for the quarter, topping analysts’ consensus estimates of ($0.78) by $1.33. The business had revenue of $2.80 billion during the quarter, compared to analysts’ expectations of $2.53 billion. Moderna had a negative net margin of 68.84% and a negative return on equity of 10.23%. The company’s quarterly revenue was down 44.9% on a year-over-year basis. During the same quarter in the previous year, the company earned $3.61 earnings per share. Equities research analysts forecast that Moderna, Inc. will post -7.48 earnings per share for the current fiscal year.

Institutional Trading of Moderna

Several large investors have recently bought and sold shares of the business. Vanguard Group Inc. grew its stake in Moderna by 22.6% during the 4th quarter. Vanguard Group Inc. now owns 33,907,072 shares of the company’s stock valued at $3,372,058,000 after acquiring an additional 6,248,623 shares in the last quarter. Wellington Management Group LLP lifted its holdings in shares of Moderna by 28.8% in the 4th quarter. Wellington Management Group LLP now owns 7,225,579 shares of the company’s stock worth $718,584,000 after acquiring an additional 1,614,460 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Moderna by 1.3% in the 1st quarter. Geode Capital Management LLC now owns 6,244,957 shares of the company’s stock worth $957,063,000 after acquiring an additional 77,265 shares during the last quarter. Morgan Stanley lifted its holdings in shares of Moderna by 19.1% in the 4th quarter. Morgan Stanley now owns 4,187,353 shares of the company’s stock worth $752,133,000 after acquiring an additional 670,284 shares during the last quarter. Finally, The Manufacturers Life Insurance Company lifted its holdings in shares of Moderna by 77.3% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 3,876,147 shares of the company’s stock worth $400,367,000 after acquiring an additional 1,690,341 shares during the last quarter. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the stock. HSBC restated a “reduce” rating and set a $86.00 target price (up from $75.00) on shares of Moderna in a research report on Monday, February 26th. Royal Bank of Canada restated an “outperform” rating and set a $125.00 target price on shares of Moderna in a research report on Thursday, March 28th. Jefferies Financial Group restated a “buy” rating and set a $125.00 target price on shares of Moderna in a research report on Tuesday. William Blair restated a “market perform” rating on shares of Moderna in a research report on Monday, April 1st. Finally, Canaccord Genuity Group boosted their target price on shares of Moderna from $82.00 to $91.00 and gave the company a “hold” rating in a research report on Friday, February 23rd. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and six have assigned a buy rating to the stock. According to MarketBeat, Moderna presently has an average rating of “Hold” and an average price target of $126.49.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.